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Background and objective: In patients with alcohol dependence, ethyl-toxic damage of 
vasomotor and cardiac autonomic nerve fibers leads to autonomic imbalance with neurovascular 
and cardiac dysfunction, the latter resulting in reduced heart rate variability (HRV). Autonomic 
imbalance is linked to increased craving and cardiovascular mortality. In this study, we sought 
to assess the effects of HRV biofeedback training on HRV, vasomotor function, craving, and 
anxiety.
Methods: We conducted a randomized controlled study in 48 patients (14 females, ages 25–59 years) 
undergoing inpatient rehabilitation treatment. In the treatment group, patients (n=24) attended 
six sessions of HRV biofeedback over 2 weeks in addition to standard rehabilitative care, 
whereas, in the control group, subjects received standard care only. Psychometric testing for 
craving (Obsessive Compulsive Drinking Scale), anxiety (Symptom Checklist-90-Revised), 
HRV assessment using coefficient of variation of R-R intervals (CVNN) analysis, and 
vasomotor function assessment using laser Doppler flowmetry were performed at baseline, 
immediately after completion of treatment or control period, and 3 and 6 weeks afterward 
(follow-ups 1 and 2).
Results: Psychometric testing showed decreased craving in the biofeedback group immediately 
postintervention (OCDS scores: 8.6±7.9 post-biofeedback versus 13.7±11.0 baseline [mean ± 
standard deviation], P,0.05), whereas craving was unchanged at this time point in the control 
group. Anxiety was reduced at follow-ups 1 and 2 post-biofeedback, but was unchanged in the 
control group (P,0.05). Following biofeedback, CVNN tended to be increased (10.3%±2.8% 
post-biofeedback, 10.1%±3.5% follow-up 1, 10.1%±2.9% follow-up 2 versus 9.7%±3.6% 
baseline; P=not significant). There was no such trend in the control group. Vasomotor function 
assessed using the mean duration to 50% vasoconstriction of cutaneous vessels after deep inspi-
ration was improved following biofeedback immediately postintervention and was unchanged 
in the control group (P,0.05).
Conclusion: Our data indicate that HRV biofeedback might be useful to decrease anxiety, 
increase HRV, and improve vasomotor function in patients with alcohol dependence when 
complementing standard rehabilitative inpatient care.
Keywords: HRV, CVNN, alcohol addiction, rehabilitation, craving, laser Doppler flowmetry
Introduction
Although multimodal alcohol rehabilitation programs are effective and widely used, 
chronic alcohol addiction is still a global medical and socioeconomic problem, with 
14.6 million affected patients in Europe alone, and is linked to increased cardiovascular 
mortality mediated by cardiac and vascular autonomic dysfunction.1,2 In patients with 
chronic alcohol addiction, ethyl-toxic damage of vasomotor and cardiac autonomic 
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nerve fibers leads to neurovascular dysfunction and decreased 
heart rate variability (HRV).3 While HRV constitutes a 
composite measure of balance of sympathetic and parasym-
pathetic tones, in alcoholic neuropathy, functional and struc-
tural damage of both sympathetic and parasympathetic nerve 
fibers individually contribute to impaired autonomic cardiac 
function.4,5 This cardiac autonomic disbalance is linked to 
increased alcohol craving.6 In turn, elevated craving is related 
to higher rates of relapse after addiction treatment.7–9 To date, 
there are no interventions to specifically treat autonomic 
dysfunction and consequentially decrease craving.
In autonomic dysfunction related to other psychiatric 
diseases such as depression and anxiety, biofeedback tar-
geting HRV via visualization of heart rate deviations on 
a computer screen was demonstrated to improve cardiac 
autonomic function by increasing HRV and to alleviate 
depressive symptoms as well as symptoms of anxiety.10,11 
A recent pilot study demonstrated that HRV biofeedback 
in a short-term setting (three single biofeedback sessions) 
is feasible to treat patients with substance use disorder, 
but found no positive effect of the intervention on craving 
symptoms or HRV.12 However, this study was limited by 
the short duration of the intervention and a heterogeneous 
study population which also included patients addicted to 
drugs. Therefore, it remains to be answered whether these 
negative results were due to overestimation of efficacy or 
heterogeneity, respectively.
In this study, we aimed to assess the hypothesis that HRV 
biofeedback increases HRV, improves peripheral autonomic 
function, and decreases craving in patients with alcohol 
dependence and might therefore supplement other treatment 
regimens of chronic alcohol addiction.
Methods
subjects and protocol
Male and female patients undergoing inpatient rehabilita-
tion treatment for alcohol use disorder were considered for 
participation in the study if they were older than 18 years of 
age, met the Diagnostic and Statistical Manual of Mental Dis-
orders, 4th Edition criteria for alcohol dependence, and had 
achieved at least 5 days of abstinence prior to study entrance. 
The presence of withdrawal syndrome was excluded by 
clinical interview and physical examination, as absence of 
withdrawal symptoms is also a prerequisite of rehabilita-
tive treatment following our institutional standard. Eligible 
patients were enrolled by the conducting study physician. 
With the use of a computer-generated random-allocation 
sequence, participants were assigned by the conducting study 
physician in a simple randomization fashion in a 1:1 ratio 
to receive either HRV biofeedback in addition to standard 
rehabilitative care or standard rehabilitative care only. To 
avoid confounding by comorbidities influencing autonomic 
functions or psychometric assessment, we excluded sub-
jects with diabetes mellitus, any heart diseases, depression, 
schizophrenia, bipolar disorder, or dementia. Additionally, 
we excluded those patients that were treated with any anti-
depressant, beta blocker, alpha blocker, or cholinergic or 
anticholinergic drug within 3 months prior to the study to 
avoid pharmacodynamic confounding. Patients in the HRV 
biofeedback group underwent three sessions of HRV biofeed-
back training per week over 2 weeks, whereas control patients 
did not undergo biofeedback. Psychometric questioning and 
assessment of autonomic functions were performed before 
the beginning of the first biofeedback session (baseline), 
immediately after completion of the last biofeedback ses-
sion, and 3 and 6 weeks after the last biofeedback session 
(follow-ups 1 and 2). Study assessments in the control group 
were performed with the same time intervals. Adherence was 
further facilitated by reminders to attend study procedures 
by our nurses, physicians, and therapists.
The application of the study intervention was per-
formed in an open setting where neither the patient nor the 
investigator was blinded to the group allocation (control or 
biofeedback). The investigator who analyzed the results of 
psychometric and autonomic assessment as well as the stat-
istician who performed statistical analysis of the data were 
blinded to group allocation.
ethical standards
Written informed consent was obtained from each participant 
prior to the study. The study was approved by the local insti-
tutional review board (Ethikkommission an der Technischen 
Universität Dresden; IRB number: EK118042010). The 
study was registered in the German Clinical Trials Register 
(DRKS00004618).
standard rehabilitative care
All study patients received standard inpatient care at the 
Heidehof Hospital rehabilitative treatment center for 
substance use disorder, Weinböhla, Saxony, Germany. Stan-
dard care comprised daily 90-minute sessions of cognitive 
behavioral group psychotherapy, individual 1-hour sessions 
of motivational interviewing and cognitive behavioral 
therapy once a week, 1-hour psychoeducational group ses-
sions three times per week, and daily 3-hour sessions of 
occupational therapy.
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hrV biofeedback
Biofeedback is a behavioral intervention that enables patients 
to achieve voluntary control over physiological processes 
due to changes in behavior. Electronic measurements of a 
physiological function (eg, HRV) are coupled with a feed-
back signal that changes whenever patients succeed or fail 
to achieve the desired changes in bodily processes due to 
their behavioral modifications (eg, breathing). In our study, a 
validated HRV biofeedback system (StressPilot™; BioSign, 
Ottenhofen, Germany) was used as described previously.11 
In brief, patients would sit in a comfortable chair in front 
of a computer monitor. The pulse wave was continuously 
measured in the earlobe, and HRV was calculated. Real-time 
visualization of HRV was achieved by a digital balloon on the 
computer screen which moved up and down proportionally 
reflecting the amplitude of HRV. With an increase or decrease 
in HRV the balloon was visualized as either rising or falling 
on the screen. At the beginning of the HRV biofeedback 
training, patients were orally instructed by the study physi-
cian to breathe at a given frequency of six cycles per minute 
following the given pacing stimulus, as this frequency was 
previously shown to yield maximum amplitudes of HRV.13,14 
As breath-pacing stimulus, we used a bar on the computer 
screen that moved up and down to indicate whether patients 
should breathe in or out. Thus, paced breathing at six cycles 
per minute to increase HRV in a visual biofeedback setting 
was the intervention in this study. HRV biofeedback was 
conducted for 20 minutes at each session. Patients in the 
HRV biofeedback group underwent three sessions of HRV 
biofeedback training per week over 2 weeks, with 2 or 3 days 
of interval between the sessions.
Psychometric testing
Psychiatric diagnoses were assessed according to DSM-IV 
by a board-certified psychiatrist and documented using the 
structured clinical interview for DSM-IV. Perceived craving 
for alcohol was assessed using the Obsessive Compulsive 
Drinking Scale (OCDS).15 This 14-item, self-administered 
instrument assesses efforts and abilities to resist thoughts of 
alcohol and drinking as well as impulses to drink. The ques-
tions use descriptors anchored on numerical ratings ranging 
from 0 to 4, where higher scores indicate higher craving 
intensities. Because of the nondrinking prerequisite of our 
institutional inpatient treatment protocol, items 7 and 8 (ques-
tions on the amount of current drinking) were excluded.16
Psychopathology was assessed using the Symptom 
Checklist-90-Revised (SCL-90-R), a self-report instrument 
composed of a 90-item questionnaire assessing the subscales 
anxiety, depression, interpersonal sensitivity, somatiza-
tion, obsessive-compulsive, phobic-anxiety, hostility, 
psychoticism, and paranoid ideation.17 Items are quantified 
by a numeric rating scale from 0 to 4 (0 meaning symp-
tom not present, 4 meaning very high symptom intensity). 
Depressive symptoms were also assessed using the Beck 
Depression Inventory-II (BDI-II). The BDI-II is a 21-item, 
self-administered questionnaire that measures affective, cog-
nitive, and autonomic characteristics of depression.18 Each 
item is rated from 0 to 3, reflecting symptom severity.
cardiac autonomic function assessment: 
hrV
Analysis of HRV was carried out using a physiological sig-
nal analysis software package (Chart 5®; AD Instruments, 
Castle Hill, Australia) as previously described.19 Briefly, the 
electrocardiogram signal was digitized using a sample rate 
of 400 per second. HRV was assessed following a resting 
period of 10 minutes. Respiration was monitored by regis-
tration of chest movements using a thoracic belt respiration 
transducer (Pneumotrace®II 1132; UFI, Morro Bay, CA, 
USA). The coefficient of variation of R-R intervals (CVNN) 
was calculated from 200 heartbeats following manual arte-
fact removal, and spectral power analysis was carried out 
by means of a fast Fourier transformation. Absolute power 
values were assessed for two frequency bands: low frequency 
(LF), 0.04–0.15 Hz; and high frequency (HF), to 0.15–0.4 
Hz, as well as for total power (TP).
To determine the HRV under paced breathing, subjects 
were instructed to breathe deeply at a frequency of six cycles 
per minute. This pattern of paced breathing was achieved 
by asking the participants to synchronize their breathing 
with breathe-in and breathe-out guiding tones given via 
headphones. The HRV parameters CVNN, LF, HF, and TP 
were calculated in the same fashion as in the abovementioned 
resting condition analyses.
Vasomotor autonomic function: laser 
Doppler flowmetry
Laser Doppler flowmetry (LDF) was used to quantify vaso-
constrictory responses of cutaneous blood vessels induced 
by sympathetic stimulation. The cutaneous blood flow 
was measured in relative units using a laser Doppler flow 
meter (Periflux®; Perimed, Järfälla, Sweden) as previously 
described.20 Briefly, the laser Doppler probe was affixed to the 
palmar aspect of the distal phalanx of the index to quantify 
arterial, capillary, and venous erythrocyte flow at a depth of 
2 mm. After a resting period of 10 minutes, patients were 
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instructed to take a single deep breath. The decrease and 
consecutive increase of cutaneous flow provoked by deep 
respiration (also referred to as inspiratory gasp response) 
was evaluated to assess sympathetic vasomotor function 
with temporal resolution: durations to 50% constriction 
(∆t50%down) and 50% redilation of cutaneous vessels 
(∆t50%up) were calculated.
statistics
Statistical analyses were performed using the Sigma Stat® 
software package (Jandel, San Rafael, CA, USA). A power 
calculation was performed prior to the study. Based on the 
results of a previous study observing a standard deviation of 
2.2 in CVNN, the primary outcome variable in our study, the 
sample size of n=48 was estimated, to result in a difference of 
19.2% between HRV biofeedback and control with a power 
of 0.8.21 Outcome data are expressed as means and standard 
deviations. Psychometric measures and measures of autonomic 
function were compared between patients undergoing HRV 
biofeedback and control patients using a one-way analysis 
of variance procedure for repeated measurements following 
testing for normality and equality of variances. Statistical 
significance was accepted at P,0.05. Wherever significant, 
Bonferroni post hoc tests were used for comparisons between 
groups. t-tests were used to test for baseline intergroup differ-
ences in age, sex, size, weight, tobacco use, and most frequent 
alcohol-related comorbidities. A multivariate sequential 
regression model was built to impute missing data.
Results
Demographic and baseline parameters
We included 48 patients with alcohol dependence (34 males 
and 14 females; ages 25–59 years; 42±7.8, mean ± standard 
deviation). Between the biofeedback group and the control 
group, there were no differences in baseline characteristics 
including age, sex, weight, size, tobacco use, and alcohol-
related comorbidities (Table 1). We documented three 
screening failures: two patients fulfilled the exclusion crite-
rion depression, and one patient decided to leave our clinic 
immediately after the screening procedure.
Missing data and adherence
The total fraction of missing data in our dataset was 5.4%. 
All missing data were missing completely at random. These 
missing data were distributed among time points of assess-
ment as follows: 31.6% at baseline, 21% immediately after 
completion of HRV biofeedback or control interval, 31.6% 
at follow-up 1, and 15.8% at follow-up 2. In HRV assess 
(CVNN, LF, HF, TP), we noted a total of 13.5% missing 
data in the intervention group and 6.5% in the control group. 
Missing data in the HRV biofeedback group occurred in 
seven patients (29.2%). In the control group, missing data 
occurred in four patients (16.7%). In vasomotor assessment 
(∆t50%down, ∆t50%up) and psychometric testing (OCDS, 
SCL-90-R, SCL-90-R anxiety, SCL-90-R depression, 
BDI-II), no missing data were noted. All missing data were 
due to technical recording errors. In our study, there were no 
dropouts and no patients lost to follow-ups. Adherence to the 
study protocol was achieved by integrating the study protocol 
into the rehabilitative inpatient treatment protocol of our 
clinic. Since patients are treated in our clinic over 12 weeks, 
we were able to perform all follow-up measurements during 
the inpatient period of treatment.
craving
We observed a decrease in craving measured by the OCDS 
in the HRV biofeedback group immediately after completion 
of the intervention and at follow-ups 1 and 2 compared to 
baseline (Table 2). In the control group, OCDS score was also 
decreased, but this reduction occurred after a delay, namely, 
at follow-ups 1 and 2.
anxiety and depression
In the HRV biofeedback group, anxiety assessed using the 
SCL-90-R anxiety items was decreased at follow-ups 1 and 2 
when compared to baseline, but there was no such change in 
the control group (Table 2). Opposing the observed reduc-
tion of anxiety after HRV biofeedback, the total SCL-90-R 
score (a composite measure of psychopathology) as well as 
depression assessed using BDI-II and SCL-90-R depression 
items were unchanged in both groups at each time point of 
evaluation (Table 2).
Table 1 Demographic characteristics
HRV biofeedback  
(n=24)
Control
(n=24)
P-value
age (years) 40 (±7) 44 (±8) 0.06
Weight (kg) 72 (±11) 74 (±19) 0.3
size (cm) 174 (±9) 174 (±10) 0.49
sex (%) 70.8 m, 29.2 f 70.8 m, 29.2 f 0.5
Tobacco use (%) 79 75 0.36
comorbidities
Neuropathy (%) 33.3 16.7 0.09
hepatic steatosis (%) 20.8 37.5 0.09
liver cirrhosis (%) 4.2 12.5 0.07
Notes: There were no differences in size, weight, sex, tobacco use, and comorbidities 
between groups. Data are expressed as either % or mean±standard deviation.
Abbreviations: f, female; hrV, heart rate variability; m, male.
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cardiac autonomic function: hrV
We noted a nonsignificant trend toward increase in CVNN 
following HRV biofeedback training compared to baseline 
and control, both under resting conditions (Figure 1) and 
under paced breathing (Figure 2). The spectral analysis 
parameters LF, HF, and TP assessed under resting conditions 
were unchanged after HRV biofeedback training compared to 
baseline and control (Table 3). This was also true for paced 
breathing (Table 4).
Vasomotor autonomic function
Vasomotor function assessed using ∆t50%down after deep 
inspiration was increased in the biofeedback group imme-
diately after biofeedback training compared to baseline, but 
there was no such change at follow-ups 1 and 2 (Figure 3).
In the control group, there was no such change. ∆t50%up 
was unchanged in the biofeedback group at each time point 
of evaluation compared with baseline and also remained 
unchanged in the control group (Figure 4).
Discussion
The major findings of our study are that patients with alco-
hol dependence in rehabilitative treatment receiving HRV 
biofeedback 1) perceived reduction of craving sooner than 
patients receiving only rehabilitative care but no HRV bio-
feedback; 2) showed a decrease in anxiety following the 
intervention; 3) tended to show improved cardiac autonomic 
function, reflected by a trend toward increased HRV post-
biofeedback; and 4) showed improved vasomotor function 
after completion of training.
Table 2 Psychometric evaluation
Intervention Time Scale
OCDS
craving
SCL-90-R
total
SCL-90-R
anxiety
SCL-90-R
depression
BDI-II
depression
hrV biofeedback Baseline 13.7 (±11.0) 46.6 (±33.5) 5.8 (±4.5) 9.7 (±7.2) 7.6 (±6.0)
n=24 Postintervention 8.6 (±7.9)* 38.0 (±37.0) 3.7 (±5.1) 7.4 (±7.9) 7.0 (±9.1)
Follow-up 1 7.5 (±6.9)* 30.3 (±25.4) 2.9 (±3.0)* 5.9 (±6.0) 5.8 (±9.1)
Follow-up 2 7.6 (±6.7)* 31.4 (±21.9) 2.7 (±2.9)* 5.8 (±4.8) 5.3 (±8.2)
control Baseline 11.6 (±7.4) 45.3 (±45.8) 3.6 (±3.7) 10.0 (±7.4) 9.0 (±7.3)
n=24 Postintervention 7.2 (±7.8) 37.0 (±28.9) 3.1 (±2.9) 8.6 (±7.3) 7.2 (±6.6)
Follow-up 1 3.6 (±3.6)* 37.8 (±36.9) 2.8 (±2.7) 7.5 (±8.2) 6.5 (±8.8)
Follow-up 2 3.2 (±3.6)* 33.0 (±31.5) 2.2 (±1.9) 6.8 (±8.1) 5.7 (±7.6)
Notes: Decreases in craving were noted in the hrV biofeedback group and with a delay in the control group, whereas anxiety was decreased only in the biofeedback group. 
Data are expressed mean±standard deviation. *P,0.05 versus baseline. in the control group, the term “postintervention” refers to the post-control period.
Abbreviations: BDi-ii, Beck Depression inventory-ii; hrV, heart rate variability; OcDs, Obsessive compulsive Drinking scale; scl-90-r, symptom checklist-90-revised.
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Figure 1 cVNN under resting conditions.
Notes: The bar graph illustrates a trend toward increased cVNN in hrV biofeedback-
treated patients, indicating possible improved function of cardiac autonomic nerve 
fibers. Data are presented as mean±standard deviation. P=ns compared to baseline 
and control. hrV biofeedback: n=24; control: n=24. in the control group, the term 
“postintervention” refers to the post-control period.
Abbreviations: CVNN, coefficient of variation of R-R intervals; HRV, heart rate 
variability; ns, not significant.
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Figure 2 cVNN under paced breathing conditions.
Notes: The bar graph illustrates a trend toward increased cVNN in hrV biofeedback-
treated patients, indicating possible improved function of cardiac autonomic nerve 
fibers. Data are presented as mean±standard deviation. P=ns compared to baseline 
and control. hrV biofeedback: n=24; control: n=24. in the control group, the term 
“postintervention” refers to the post-control period.
Abbreviations: CVNN, coefficient of variation of R-R intervals; HRV, heart rate 
variability.
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cardiac autonomic function and psychiatric symptoms.10,11 
In fact, an open-label study in 14 patients with depression 
undergoing HRV biofeedback training demonstrated an 
increase in HRV which was paralleled by a decrease of 
depressive symptoms and anxiety.11 This study was limited 
by lack of randomization and control group. However, its 
results are in line with our observation of decreased anxiety 
and tendentially increased HRV in patients with alcohol 
dependence. These beneficial effects on cardiac autonomic 
function and anxiety might also explain our observation 
of improved craving reduction following biofeedback, 
since craving was previously linked to increased anxiety 
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Baseline Postintervention Follow-up 1 Follow-up 2
HRV biofeedback Control
Figure 3 Vasomotor function: ∆t50%down.
Notes: after hrV biofeedback (but not in the control group), ∆t50%down was 
increased, indicating possible improved function of vasomotor autonomic nerve 
fibers. Data are presented as mean±standard deviation. *P,0.05 versus baseline. hrV 
biofeedback: n=24; control: n=24. in the control group, the term “postintervention” 
refers to the post-control period.
Abbreviations: ∆t50%down, mean duration to 50% vasoconstriction; hrV, heart 
rate variability; ns, not significant.
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Figure 4 Vasomotor function: ∆t50%up.
Notes: ∆t50%up was unchanged in both the hrV biofeedback group and in the 
control group. Data are presented as mean±standard deviation. P=ns compared to 
baseline and control. hrV biofeedback: n=24; control: n=24. in the control group, 
the term “postintervention” refers to the post-control period.
Abbreviations: ∆t50%up, duration to 50% redilation of cutaneous vessels; hrV, 
heart rate variability; ns, not significant.
Table 3 hrV parameters under resting conditions: spectral analysis
Parameter Resting condition
HRV biofeedback  
n=24
Control
n=24
Baseline
hF (ms2) 809.5 (±1,565.0) 438.6 (±606.6)
lF (ms2) 656.0 (±858.0) 463.1 (±462.4)
TP (ms2) 1,901.6 (±2,096.9) 2,395.6 (±3,915.7)
Postintervention
hF (ms2) 762.3 (±1,198.9) 662.8 (±1,426.1)
lF (ms2) 673.7 (±597.0) 659.5 (±1,266.3)
TP (ms2) 1,946.0 (±1,933.3) 1,839.5 (±3,181.2)
Follow-up 1
hF (ms2) 420.2 (±431.3) 568.6 (±1,231.2)
lF (ms2) 695.3 (±748.0) 1,123.7 (±3,681.3)
TP (ms2) 2,110.8 (±2,331.3) 2,382.4 (±5,068.1)
Follow-up 2
hF (ms2) 358.7 (±304.7) 428.2 (±615.5)
lF (ms2) 675.0 (±436.8) 546.0 (±715.0)
TP (ms2) 1,638.3 (±926.4) 1,768.4 (±2,029.2)
Notes: hrV was unchanged in both the control group and the biofeedback group. 
in the control group, the term “postintervention” refers to the post-control period. 
Data are expressed as mean±standard deviation. P=ns.
Abbreviations: hF, high frequency; hrV, heart rate variability; lF, low frequency; 
TP, total power; ns, not significant.
Table 4 hrV parameters under paced breathing: spectral analysis
Parameter Paced breathing
HRV biofeedback  
n=24
Control
n=24
Baseline
hF (ms2) 1,565.4 (±1,440.9) 898.8 (±1,160.3)
lF (ms2) 4,795.8 (±4,030.1) 3,649.6 (±4,627.0)
TP (ms2) 7,024.2 (±6,344.5) 4,989.0 (±5,902.0)
Postintervention
hF (ms2) 1,071.3 (±1,277.2) 774.5 (±1,231.5)
lF (ms2) 5,578.4 (±3,589.0) 2,856.4 (±3,849.6)
TP (ms2) 7,269.1 (±5,231.7) 4,136.0 (±4,893.3)
Follow-up 1
hF (ms2) 868.6 (±734.2) 871.0 (±1,894.9)
lF (ms2) 5,008.0 (±3,532.7) 3,382.0 (±6,886.9)
TP (ms2) 6,476.6 (±4,611.0) 4,981.0 (±9,385.2)
Follow-up 2
hF (ms2) 1,043.7 (±1,120.3) 1,067.6 (±1,847.6)
lF (ms2) 4,085.6 (±2,530.2) 4,009.2 (±5,917.2)
TP (ms2) 6,110.1 (±4,023.6) 5,657.6 (±8,009.5)
Notes: hrV was unchanged in both the control group and the biofeedback 
group. Data are expressed as mean±standard deviation. all hrV parameters were 
unchanged in both groups at each time point of assessment (p=ns). in the control 
group, the term “postintervention” refers to the post-control period.
Abbreviations: hF, high frequency; hrV, heart rate variability; lF, low frequency; 
TP, total power; ns, not significant.
The mechanism whereby HRV biofeedback improves 
autonomic functions is not fully elucidated. It was hypoth-
esized that the intervention increases balance between the 
sympathetic and parasympathetic branches, but the contri-
bution of each branch remains speculative.12 In psychiatric 
diseases related to a shift toward increased sympathetic 
and decreased parasympathetic tone such as anxiety and 
depression, HRV biofeedback was shown to improve both 
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and impaired autonomic responsivity.22 Additionally, our 
observation of decreased craving after HRV biofeedback is 
consistent with previous studies on HRV biofeedback report-
ing reduced food craving in high food cravers and attenuated 
substance craving in individuals with posttraumatic stress 
disorders.23,24 These studies support the possible explanation 
of a reduction in craving through HRV biofeedback which 
is mediated by improvement of autonomic adaptive capac-
ity. However, it remains to be answered how changes in the 
sympathetic/parasympathetic balance convert into alleviation 
of craving. Our observation of improved vasomotor function 
might indicate that a decrease in sympathetic outflow due 
to HRV biofeedback contributes to attenuation of craving, 
as the measures of cutaneous vasoconstriction used in our 
study constitute direct indicators of sympathetic vasomotor 
function.25,26 In accordance with this assumption, a previ-
ous controlled study showed increased sympathetic tone in 
patients with alcohol dependence when being exposed to 
craving induced by olfactory stimuli (sniffing of preferred 
alcoholic beverages).27 We also noted an improvement in 
craving in the control group, which might be explained by the 
effectiveness of our standard rehabilitative treatment. How-
ever, the observation that improvement in craving occurred 
earlier in the HRV biofeedback group is encouraging, as it 
might indicate effectiveness of the intervention which even 
leads to an amplification of improvement of craving through 
standard care. Therefore, our data might support the poten-
tial use of HRV biofeedback as supplementary treatment of 
alcohol use disorder.
Even though the aforementioned studies lend support 
to a predominant sympathetic mechanism whereby HRV 
biofeedback improves craving, the anatomo-physiological 
link between decreased sympathetic tone and reduced crav-
ing remains to be elucidated. Peripheral sympathetic tone 
was shown to be regulated by sympathetic centers in the 
hypothalamus and brainstem, whereas the development of 
craving appears to be caused by functional alterations in lim-
bic and prefrontal regions. Therefore, it might be speculated 
that communicating pathways between limbic/prefrontal 
and hypothalamic/brainstem regions might play a role in the 
beneficial effects of HRV biofeedback on craving.28,29
Although our observations of improved autonomic func-
tions and decreased craving and anxiety appear to confirm 
the therapeutic value of HRV biofeedback in the treatment 
of patients with alcohol dependence, some limitations of our 
study have to be mentioned. First, the observed increase in 
HRV did not reach statistical significance. Since a type II 
error is unlikely, as our study population size was calculated 
prior to conduction of the study, we speculate that late-stage 
structural ethyl-toxic damage of cardiac autonomic fibers 
might have caused reduced responsivity to HRV biofeed-
back. However, even in our patients with late-stage alcohol 
use disorder, we observed a trend toward improved HRV. 
This beneficial effect might be stronger in earlier stages of 
the disease, where nerve fiber damage is less irreversible. 
Our results therefore warrant a follow-up study to investi-
gate disease stage-specific effects of HRV biofeedback in 
patients with alcohol dependence. This follow-up investiga-
tion should also control for structural measures of autonomic 
fiber neuropathy, such as intraepidermal nerve fiber density 
assessment and explore the association of alcohol use dis-
order severity measures and observed effect sizes. Second, 
our study was limited by the lack of an active control condi-
tion using a sham intervention, where control patients are 
sitting in front of the computerized biofeedback system but 
are receiving neither breathing instructions nor actual HRV 
measurement. Although we refrained from an active control to 
avoid inpatients from the intervention group communicating 
breathing instructions to the control patients in our clinic, a 
sham intervention in the control group might have been more 
effective in controlling for potential placebo effects of the 
intervention. Therefore, follow-up research should include 
sham biofeedback and minimize the possibility of intergroup 
conversations on breathing instructions, eg, in a multicentric 
setting. The absence of an active control intervention in our 
control group might have jeopardized the robustness of physi-
ological autonomic function measures and might explain the 
discrepancy of improved psychometric measures and only 
tendentially increased HRV. However, since our observa-
tions of decreased anxiety and craving indicate that HRV 
biofeedback might be effective as supplementary treatment in 
patients addicted to alcohol, this study may form a basis for a 
larger follow-up study which also includes an active control 
setting to elucidate to what extent these beneficial effects 
convert into improvement of autonomic functions. Third, 
since we performed a monocenter study in a limited number 
of patients, we cannot comment on the external validity of 
our findings, which should be assessed using a multicentric 
approach. Last, we used LDF to assess vasomotor function, 
a technique that is limited by interindividual variability and 
single-point assessment of cutaneous blood flow. Conse-
quently, LDF was shown to be insensitive in the detection of 
vasomotor dysfunction in individual patients. However, the 
technique was also shown to reliably detect group differences 
between patients with neuropathic vasomotor dysfunction 
and healthy subjects.30–32 Consistent with these previous stud-
ies, we observed a group difference in vasomotor function 
assessment between patients undergoing HRV biofeedback 
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and control patients. Future studies using HRV biofeedback 
should also include alternative vasomotor function techniques 
that have lower variability and allow for cutaneous blood flow 
evaluation with both temporal and spatial resolution, such as 
regression thresholding-based assessment of the laser Doppler 
imaging axon-reflex flare area.33
Taken together, our findings viewed in conjunction with 
the current literature suggest that HRV biofeedback might 
be an effective supplement to rehabilitative inpatient care of 
patients with alcohol addiction.
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